For Interventional Cardiologists
Final Results from the National Cardiogenic Shock Initiative (NCSI) Study Report Demonstrate Benefit of Early Impella Cardiac Unloading
The final results of the physician-led NCSI Study demonstrate a 71% survival to discharge with greater than 90% native heart recovery when best practices are used, including placement of an Impella heart pump prior to revascularization (PCI).
Explore the Latest Presented Data From the National Cardiogenic Shock Initiative (NCSI) Study
Native heart recovery at discharge1
NCSI Study is an independent, physician-led, national, multicenter initiative aimed at improving mortality in patients with AMI cardiogenic shock (AMICS).1 Based on the consistent finding of good survival outcomes with early hemodynamic support with Impella therapy from the IQ database and cVAD study, a best practices algorithm for the treatment of patients with AMICS was established. The NCSI Study algorithm includes identifying shock early, use of Impella therapy before PCI, reducing the use of inotropes, and the use of invasive hemodynamic monitoring to aid in escalation and weaning.
As of April 2021, 406 patients with AMI cardiogenic shock from 80 participating sites treated using Impella best practices demonstrated 71% survival at discharge with more than 90% native heart recovery.1
View Additional NCSI Study Resources
Achieving >70% AMICS Survival: Insights From National Cardiogenic Shock Initiative Study
William O'Neill, MD, discusses the application of best practices from the NCSI Study.
About 40% of AMICS Patients Develop Right Ventricular Dysfunction
Babar Basir, DO, discusses findings on right heart dysfunction from the NCSI Study.
Using the NCSI Study Algorithm
Inder Singh, MD, describes evaluating the patient with respect to a cardiogenic shock algorithm.
Efficacy and Safety of all Impella Heart Pump Use in Japanese Patients With Drug-Resistant Acute HF
Junya Ako, MD, presents the interim analysis of data from 819 patients from the Japanese Registry for Percutaneous VAD (J-PVAD). J-PVAD is an investigator-initiated, prospective study of all Impella use in Japan with the goal to safely and effectively disseminate the use of Impella with appropriate use guidance.
Conditions & Therapies
Learn more about effective hemodynamic support in elective and urgent high-risk PCI with the Impella® platform.
AMI Cardiogenic Shock
Reverse the downward spiral of cardiogenic shock by identifying patients early, treating them with a proven protocol and following them with hemodynamic monitoring.
- Basir, B., et al. (2021). SCAI Scientific Sessions